Abstract :
[en] Even though an estimated 10e20 million people worldwide are infected with the oncogenic retrovirus, human T-lymphotropic virus type 1 (HTLV-1), its epidemiology is poorly understood, and little effort has been made to reduce its prevalence. In response to this situation, the Global Virus Network launched a taskforce in 2014 to develop new methods of prevention and treatment of HTLV-1 infection and promote basic research. HTLV-1 is the etiological agent of two life-threatening diseases, adult T-cell leukemia and HTLV-associated myelopathy/tropical spastic paraparesis, for which no effective therapy is currently available. Although the modes of transmission of HTLV-1 resemble those of the more familiar HIV-1, routine diagnostic methods are generally unavailable to support the prevention of new infections. In the present article, the Taskforce proposes a series of actions to expand epidemiological studies; increase research on mechanisms of HTLV-1 persistence, replication and pathogenesis; discover effective treatments; and develop prophylactic and therapeutic vaccines.
Name of the research project :
the Interuniversity Attraction Poles (IAP)
Program “Virus-host interplay at the early phases of infection” BELVIR initiated by the Belgian Science Policy Office
AgricultureIsLife
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique
Télévie
BELSPO - Politique scientifique fédérale
Belgian Foundation Against Cancer
CAC - Centre anticancéreux près l'Université de Liège asbl
Fonds Léon Fredericq
ULiège. GxABT - Liège Université. Gembloux Agro-Bio Tech
ULg FSR - Université de Liège. Fonds spéciaux pour la recherche
Scopus citations®
without self-citations
73